Skip Navigation
Menu
Letters |7 July 2015

Anakinra Improves Pyoderma Gangrenosum in Psoriatic Arthritis: A Case Report

Marie Acquitter, MD; Patrice Plantin, MD; Ingrid Kupfer, MD; Henri Auvinet, BS; Thierry Marhadour, MD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
×
FULL TEXT
Background: Anakinra is an antagonist of the receptor for interleukin-1. Pyoderma gangrenosum is a poorly understood condition that causes necrosis of skin and other tissue.
Objective: To report the first case to our knowledge of anakinra improving pyoderma gangrenosum in a patient with psoriatic arthritis.
Case Report: We assumed the care of a 46-year-old white woman with a painful, deep ulcer in the left leg. She was diagnosed with plaque psoriasis at age 7 years and had experienced symmetrical, destructive axial and peripheral polyarthritis since age 18 years. She was negative for rheumatoid factor and anti–cyclic citrullinated peptide antibodies but positive for HLA-B27 antigen. Computed tomography documented sacroiliitis typical of psoriatic arthritis. The patient had no extra-articular damage associated with her rheumatism, which had been treated with methotrexate since diagnosis. She also had previously received prednisone, sulfasalazine, and infliximab, but treatment with these agents was discontinued in 2004 because of infection after knee arthroplasty.
FULL TEXT
PDF
Not Available
Citations
Citation

Acquitter M, Plantin P, Kupfer I, Auvinet H, Marhadour T. Anakinra Improves Pyoderma Gangrenosum in Psoriatic Arthritis: A Case Report. Ann Intern Med. 2015;163:70–71. doi: 10.7326/L15-5107

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2015;163(1):70-71.

DOI: 10.7326/L15-5107

11 Citations

Related Articles
Annals for Educators - 16 October 2018
Annals of Internal Medicine; 169 (8): ED8
Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial
Annals of Internal Medicine; 166 (8): 557-564
Annals for Educators - 5 January 2016
Annals of Internal Medicine; 164 (1): ED1
Review: Methotrexate does not increase risk for lung disease in psoriasis, psoriatic arthritis, or IBD
Annals of Internal Medicine; 163 (2): JC7
View MoreView Less

Journal Club
Review: Methotrexate does not increase risk for lung disease in psoriasis, psoriatic arthritis, or IBD
Annals of Internal Medicine; 163 (2): JC7
View MoreView Less

Related Topics
Rheumatology

Rheumatology.

PubMed Articles
Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.
Front Pharmacol 2019;10():282.
A novel mutation of interleukin-1 receptor antagonist (IL1RN) in a DIRA patient from Turkey: Diagnosis and treatment.
Turk J Pediatr 2018;60(5):588-592.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×